Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors in Bosnia and Herzegovina
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 800
- 试验地点
- 2
- 主要终点
- The number and percentage of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline.
研究概览
简要总结
This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months. Data collection for each patient will take place at a single visit. The investigators will complete Case Report Form (CRF) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.
详细描述
Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Bosnia and Herzegovina
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients, treated with one HMG-CoA reductase inhibitors for at least 6 months without changing the dose for the last 4 weeks at least
- •All patients must sign informed consent form
排除标准
- •Patients who have not signed the Informed Consent Form
- •Patients with contraindication for the treatment with HMG-CoA reductase inhibitors as per SmPC approved in Bosnia and Herzegovina
结局指标
主要结局
The number and percentage of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline.
时间窗: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
次要结局
- The number and percentage of patients reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline.(During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated)
- The number and percentage of patients with high cardiovascular risk reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline.(During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated)
- The number and percentage of patients with high cardiovascular risk reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline.(During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated)